10x Genomics is trading 4.73% up at $69.52 after announcing a collaboration with Lunit to combine AI-powered pathology analysis with spatial molecular data for oncology biomarker discovery.
- The partnership integrates Lunit SCOPE IO with 10x Genomics’ research workflows, potentially strengthening its precision-oncology platform.
- Broader risk-on sentiment is also supportive, with major U.S. indexes rising more than 0.5% on September 11, 2026.